Disease relevance of Betnovate

• In a combined group of atopic dermatitis patients (n = 14) and healthy volunteers (n = 12), 0.3% tacrolimus, 0.1% tacrolimus, betamethasone-valerate, and a vehicle control were applied in a randomized order to nonsymptomatic, 4 cm x 4 cm regions of abdominal skin [1].
• The number of patients with dermatitis from applied betamethasone-17-valerate ointment, which incorporated hydrogenated lanolin, rapidly increased in Japan after 1971 [2].
• A clinical evaluation was carried out in 19 patients with lichen ruber planus to assess the effectiveness of 0.05% betamethasone-17,21-dipropionate ointment in the treatment of patients whose lesions had developed resistance to prolonged treatment with 0.1% betamethasone-17-valerate ointment [3].
• A double-blind trial of budesonide ointment and betamethasone-17-valerate ointment in psoriasis [4].

High impact information on Betnovate

• Correlating with the disappearance of inflammatory cells, we observed a depletion of inflammatory dendritic epidermal cells and T cells on pimecrolimus and BMV treatment [5].
• The effect of pimecrolimus and BMV on Langerhans cells (LCs), inflammatory dendritic epidermal cells, and T cells was investigated by using immunofluorescence and flow-cytometry techniques [5].
• We conclude from our measurements that the change of the Tyr HC2 beta-configuration induces heme-apoprotein interaction via the Tyr HC2 beta-Val FG5 beta H-bond, which are transduced to the heme via central and peripheral coupling [6].
• Effect of betamethasone-17-valerate on synthesis of collagen and prolyl hydroxylase activity in chick embryo tendon cells [7].
• In this study, several anti-inflammatory drugs [beclomethasone-17,21-dipropionate (BDP), betamethasone-17-valerate (BV), triamcinolone acetonide, ECU-R2, budesonide, and prednisolone] were micronized by controlled crystallization without any milling processes [8].

Chemical compound and disease context of Betnovate

• Here we compared the in vitro skin penetration and permeation of two novel drugs used in the therapy of atopic eczema (pimecrolimus and tacrolimus) and three representative corticosteroids (betamethasone-17-valerate, clobetasol-17-propionate, and diflucortolon-21-valerate) [9].
• In a randomized, double-blind study, 7 patients hypersensitive to both FA and nickel repeatedly applied Flutivate cream containing FA or Betnovate cream not containing FA to areas of experimentally induced nickel dermatitis [10].
• Locoid vs betnovate lotion in the treatment of seborrhoeic and atopic dermatitis of the scalp [11].
• Five patients with extensive dermatitis and 5 normal subjects were treated with topical betamethasone valerate 0.1% (Betnovate, Glaxo) 19-34 g daily for 4 days [12].

Biological context of Betnovate

• Topical betamethasone-17-valerate inhibits the vasodilatation response to local non-pathological heating of rat skin [13].
• Vasoconstriction, manifest as a reduction in blood flow necessary to maintain a constant pressure, was observed over 4 h in the arteries supplying isolated abdominal skin flaps of greyhound dogs treated with intravenously administered betamethasone-17-valerate [14].
• The bioavailabilities and activities of three amcinonide preparations and Betnovate cream were assessed using three multiple-dosage regimen vasoconstrictor assays in 10 volunteers [15].
• Influence of topically applied betamethasone-17-valerate on cell cycle kinetics of human anagen hair determined by DNA flow cytometry [16].
• The majority (84%) of prescribed steroid dilutions on general practice prescription forms (F.P. 10's) were for Betamethasone-17-valerate and 83% required unrecommended diluent [17].

Anatomical context of Betnovate

• An equivalent long-term oral dose of betamethasone-17-valerate, a locally rather than a systemically active glucocorticoid, had a similar effect on the enterocytes [18].

Associations of Betnovate with other chemical compounds

• Hairless rats received maximized treatment with occluded applications of 10% fusidic acid or 4% betamethasone-17-valerate in ethanol for 72 h followed by microdialysis [19].
• Depending on the type of drug no effects (betamethasone-17-valerate), increasing particle size of the dispersions (chloramphenicol, miconazole) or phase separation upon autoclaving (high load of miconazole) was observed [20].
• Betamethasone, betamethasone-17-valerate, betamethasone-17-benzoate, and betamethasone-17,21-diproprionate were investigated for their inhbitory action on glucose-beta-phosphate dehydrogenase (G-6-PDH) activity (pure enzyme from yeast, enzyme from human skin homogenate) [21].
• Furthermore, the combined effect of CX-659S with BV was also observed on dinitrochlorobenzene (DNCB)-induced DTHR in guinea pigs [22].

Gene context of Betnovate

• The effects of topical betamethasone-17-valerate on collagen propeptide levels, collagen mRNA level, lysyl oxidase mRNA and matrix metalloproteinase (MMP)-1 and MMP-2 mRNA levels were studied in human skin [23].
• We also investigated the effect of topical glucocorticoid (betamethasone-17-valerate) and age on suction blister fluid TGF-beta1 in healthy volunteers [24].

Analytical, diagnostic and therapeutic context of Betnovate

• RESULTS: Two patients in the symptomatic group reacted to corticosteroids in patch tests, one to betamethasone-17-valerate, Hc-17-B and budesonide, and the other to budesonide and Hc-17-B [25].
• Topical betamethasone-17-valerate significantly inhibited the increase in human forearm cutaneous blood flow in response to heat of 44 degrees C, as measured by laser-Doppler velocimetry [13].
• The effect of serial dilution of betamethasone-17-valerate (Betnovate ointment) in Unguentum Merck was investigated using a single application blanching assay in 10 subjects and high performance liquid chromatography [26].

References